On Monday, Twist Bioscience Corporation (NASDAQ:TWST) reported a fourth-quarter loss per share of 59 cents, beating the consensus loss of 70 cents. Twist Bioscience reported fourth-quarter sales of $84.71 million, up 27% year-over-year, beating the consensus of $82.2 million and the management guidance of $82 million–$83 million. The company shipped products to approximately 3,562 customers in fiscal 2024, compared to approximately 3,450 in 2023. Twist shipped approximately 772,000 genes in 2024